Biofilm is a bacterial community formed when a group of microorganisms adhere to a surface and shelter inside a polymeric matrix, which is nutritious for the bacterial growth (1). This mini-ecosystem provides a safe environment for the microorganisms, protects them from antibiotics, as well as hosts defense mechanisms and immune responses (2). The arrangement of biofilm matrices varies depending on the microbial species and the growth conditions. Extracellular polymeric substances (EPS), extracellular DNA (eDNA), and proteins generally comprise the biofilm matrix (3). These matrix components are assembled into the supramolecular structures that protect bacteria from unfavorable environmental factors.
The process of biofilm formation is complex, but researchers agree that it can be broken down into a few basic steps: (Step.1) initial contact with and attachment to the surface, followed by the (Step.2) formation of micro-colonies, (Step.3) maturation and development of the biofilm architecture, and finally (Step.4) detachment and dispersion of the biofilm (4).
In spite of the fact that biofilms widely exist in nature, their importance in clinical settings, particularly in light of their role in medical-related infections, is sometimes overlooked (5). In fact, one of the most significant sources of the nosocomial infections is the spread of biofilm of bacterial populations (6). The National Institute of Health (NIH) has indicated that 65% of microbial and 80% of chronic infections are related to the biofilm formation (7).
Due to P. aeruginosa flexibility and strong intrinsic drug resistance, common antimicrobial treatments such as antibiotics, including carbapenems, aminoglycosides, cephalosporins, and ureidopenicillins demonstrate low efficiency against this bacterium (8).
In other words, these bacteria are resistant to the majority of the current antimicrobial treatments due to the bacteria innate resistance mechanisms, such as efflux pumps and multidrug resistance, latent persister cells, and low antibiotic penetration (9). The ability of P. aeruginosa to create biofilms, which protect them from environmental stressors, gives them the capability for colonization and long-term survival. P. aeruginosa has been known as one of the main pathogens in device-associated nosocomial infections (10). Biofilm produced from this pathogen is responsible for 10-11% of all nosocomial infections, and contributes to developing infections in the urinary, respiratory, and wound settings (11, 12). It can also lead to bacteremia, especially in hospitalized patients in the ICU who frequently have hemodynamic instability, and respiratory insufficiency that need mechanical lung ventilation (13, 14). Moreover, combating P. aeruginosa biofilms is critical, especially in hospital settings, because of some other important reasons such as contamination of medical devices, evasion of the host's immune system, increased mortality and morbidity, and the hospital-acquired infections (15, 16).
As of today, ozone therapy has been considered an alternative and non-invasive treatment, which has a number of applications in various fields including medicine, dentistry, water treatment, and food industry (17, 18). The ozonated olive oil is prepared using pure olive oil through ozonation mechanism, in which ozone reacts with the double bonds of carbon in unsaturated fatty acids, and produces different oxygenated species including hydro-peroxides, ozonizes, aldehydes, and di/poly-peroxides, which are responsible for the bacteriostatic and bactericidal activities of the ozonated olive oil (19). This mechanism, ozonolysis, proposed by Criegee in 1975 has been widely accepted by many researchers (20).
Although there are several studies regarding the efficacy of different ozonated oils and water on biofilm elimination, the anti-biofilm effect of ozonated olive oil on P. aeruginosa, which causes device-associated nosocomial infections has not yet been studied. This study aimed to investigate the effectiveness of different concentrations of the ozonated olive oil on P. aeruginosa biofilms.
2-1- Ozonated Olive Oil Preparation
The ozonated olive oil was prepared using pure olive oil through ozonation mechanism, which was discussed in our previous study (21). The physicochemical properties of the extra virgin and ozonated olive oil including iodin index, peroxide value, and acid value were determined by the specific procedures (22). Moreover, to prepare different concentrations of the ozonated olive oil (% v/v), a suitable amount of 100% supersaturated ozonated olive oil was added to the virgin olive oil, to prepare 5%, 10%, 15% and 30% ozonated olive oils.
2-2- Bacterial Strains
Two biofilm-producer strains of P. aeruginosa; POA1 and 1707, were investigated in this study. Both of these strains were obtained from Mashhad University of Medical Sciences, School of Pharmacy. The model strain P. aeruginosa PAO1 is normally used in research of virulence and biofilm stability because of its strong biofilm formation and great resistance to antibiotics and biocides (23). The Persian Type Culture Collection's PTCC 1707 is used to evaluate the antimicrobial therapies since it is a robust biofilm-former and responds well to the new therapeutic approaches (24).
The ability of different concentrations of prepared ozonated oils in preventing the bacteria from biofilm formation, elimination of the constructed biofilm, and finally penetration the biofilm to kill sheltered cells was investigated in this study.
2-3- Biofilm Preparation
P. aeruginosa was cultured on Mueller Hinton Agar (MHA) at 37°C overnight. After that, the bacterial suspension was prepared in sterile normal saline 0.9% and adjusted to 0.5 McFarland turbidity to achieve 108 CFU/mL, and then serially diluted to 106 CFU/mL. For biofilm formation, 180 μL Mueller Hinton Broth (MHB) nutrient medium enriched with 2.5% glucose was inoculated in a 96-well plate and subsequently, 20 µL of 106 CFU/mL microbial suspensions was added into each well. The microplate was incubated at 37°C for 48 hours. During this time, the medium was refreshed every 12 hours and incubated again. After 48 hours, the mixture of microbial suspension and MHB was aspirated and the wells were washed twice with sterile normal saline (25).
2-4- Inhibition of Biofilm Construction
First, 20 μl of each freshly prepared strain of P. aeruginosa (106 CFU/mL) was inoculated separately into the wells containing glucose-enriched culture medium supplemented with various concentrations of the ozonated olive oil. Each concentration was replicated thrice. The plate was incubated for 48 hour and the contents of each well were replaced with fresh ones every 12 hour. Finally, the formed biofilms were stained by crystal violet (0.03%) and the absorbance of each well was determined at 590 nm using a multi-scan plate reader (Biotek, Synergy H4). The wells with higher absorbance indicated more amounts of formed biofilm.
2-5- Degradation of Constructed Biofilm
Similar to the previous method, 20 μL of each freshly prepared strain of P. aeruginosa (106 CFU/mL) was inoculated into the wells containing glucose-enriched MHB. The medium of each well was replaced every 12 hour during 48 hour. In the last 12 hours, the medium was replaced with 200 µL glucose-enriched MHB containing different concentrations of the ozonated olive oil and incubated at 37°C for 12 hours (each concentration was repeated three times). Again, the analysis of the biofilm formation was performed via 0.03% crystal violet staining and the absorbance was determined by a plate reader at 590 nm.
2-6- Quantitative Analysis of Biofilms by Crystal Violet Assay
In brief, after aspiration of the contents of each well, the wells were washed twice with 200 μL normal saline and drained. Next, 50 μl crystal violet was added and incubated for 10 min. Afterwards, the microplate contents were removed and washed twice with 200 μL normal saline to remove unbound dye. In the next step, 200 μL 96% ethanol was added to each well to extract the bound dye. After 10 min, the contents of each well were transferred into the next well to remove the possible unwanted turbidity. Finally, the absorbance of each well was determined at 590 nm (26).
2-7- Penetration of Ozonated Olive Oil into Biofilm
As in the previous experiment, 20 μl of each freshly prepared strain of P. aeruginosa (106 CFU/mL) was inoculated into the wells containing glucose-enriched MHB. The culture medium in each well was replaced every 12 hour during 48 hour. In the last 12 hours, the medium was replaced with a 200 µL glucose-enriched medium containing various concentrations of the ozonated olive oil and incubated again for 12 hours at 37°C. After this period, the wells were replaced with 180 µL glucose-enriched culture medium plus 20 µL 2, 3, 5-triphenyl tetrazolium chloride (TTC) salt (5 mg/ml) and incubated at 37°C for 5 more hours. Finally, the absorbance of the produced red color (due to TTC reduction to triphenyl formazan), indicating the amount of the live bacteria, was determined by the plate reader at 500 nm (27).
Iodine index (g Iodine per 100g) |
Acid value (AV) (mg KOH g-1) |
Peroxide value (PV) (mmol-equv.Kg-1) |
|
81.8±1.28 | 0.28±0.02 | 10±0.12 | Virgin olive oil |
0 | 17.3±0.06 | 2439±13.3 | Ozonated olive oil |
This study evaluated the anti-biofilm efficacy of the ozonated olive oil against P. aeruginosa biofilms. The key findings were as follow: Ozonated olive oil at 5% and 10% concentrations inhibited biofilm formation by the P. aeruginosa PAO1 strain. The 15% solution completely eliminated pre-formed PAO1 biofilms, demonstrating biofilm degradation ability. While resistant to biofilm inhibition, established biofilms of the 1707 strain were removed by 5% ozonated olive oil. The ozonated oil solutions could penetrate and kill bacterial cells within the PAO1 and 1707 biofilms. In conclusion, ozonated olive oil exhibited promising multi-faceted anti-biofilm effects against P. aeruginosa, including inhibition, degradation, and penetration to the biofilms. This low-cost, eco-friendly product shows potential as an alternative disinfectant for controlling the biofilm-associated infections in the healthcare settings. However, the study focus on only two strains limits the generalizability of the outcome and in vivo evaluations are necessary to assess the real-world efficacy and safety.
The authors thank the Mashhad University of Medical Sciences, School of Pharmacy for the provision of financial support, facilities and equipment for this research.
Ethical Considerations
None.
Authors’ Contributions
Saba Dadpour, Omid Rajabi and Vahid Soheili conceived and designed the experiments. Saba Dadpour, Omid Rajabi and Vahid Soheili wrote the main manuscript text. Zahra Sabeti Noghabi and Atoosa Haghighizadeh performed the experiments. Leila Etemad analyzed the data. Saba Dadpour, Atoosa Haghighizadeh and Zahra Sabeti Noghabi reviewed and finalized the manuscript. All authors contributed to the article and approved the submitted version.
Conflicts of Interest
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |